2012-09-28 16:44:17 - New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research

This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs

Scope
* Gain insight into UCB's strategic outlook across the next 6 years.
* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Although UCB's prescription sales growth through to 2016 will be impacted by generic erosion of its biggest drug, Keppra, forecast gains associated with uptake of new offerings Cimzia and epratuzumab will drive overall growth and allow an improvement on UCB's historical performance.

Reasons to Get this Report
* Benchmark UCB's performance against

key rivals in the prescription pharmaceutical sector
* Assess how successful UCB will be in diversifying its business focus and reducing its reliance on the epilepsy market
* See how UCB proprietary biotechnology platform, gained through the acquisition of Celltech, will support UCB's expansion in the biologics drug market


Full Report Details at
- www.fastmr.com/prod/464836_ucb_sa_company_analysis.aspx


Report Table of Contents:

SCOPE OF COVERAGE

* PharmaVitae Explorer database
* Structure of analysis

* Strategic Insight
* Company Overview
* Operating Performance Analysis

EXECUTIVE SUMMARY

* Key findings
* UCB prescription pharmaceutical sales outlook
* UCB financial outlook
* SWOT analysis

* Weaknesses
* Opportunities
* Threats

STRATEGIC INSIGHT

* Key findings
* Launch/core/expiry analysis
* Strategic insight

* The Keppra franchise is forecast to be UCB's principal growth resistor
* Cimzia is forecast to be UCB's principal sales growth driver going forward
* Cimzia's commercial potential may be hampered by novel oral therapies and biosimilars for rheumatoid arthritis
* Majority stake in Meizler gives UCB access to the Brazilian pharma market

CORPORATE STRUCTURE

* Key findings
* Background
* Corporate structure

* Prescription pharmaceuticals
* Non-prescription products

* M&A history

* M&A strategy

OPERATING PERFORMANCE

* Key findings
* Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2005-11
* Operating costs and profit analysis

* Operating costs and profit analysis, 2005-11
* Operating cost ratio and profit margin analysis, 2005-11
* Operating cost ratio and profit margin analysis, 2011-17
* Operating costs and profit analysis, 2011-17

APPENDIX

* References
* Exchange rates

TABLES

* Table: Datamonitor's established pharmaceutical company coverage, 2012
* Table: UCB - key product overview ($m), 2011-17
* Table: UCB's financial performance ($m), 2011-17
* Table: UCB's launch, core, and expiry portfolio overview ($m), 2011-17
* Table: UCB's key merger and acquisition deals, 19XX-2012
* Table: Total UCB sales by business unit ($m), 2005-11
* Table: UCB's operating revenue/cost analysis ($m), 2005-11
* Table: UCB's operating cost ratio analysis (percentage of total revenues), 2005-11
* Table: UCB's operating cost ratio analysis (percentage of total revenues), 2011-17
* Table: UCB's operating revenue/cost analysis ($m), 2011-17
* Table: Exchange rates, 2012

FIGURES

* Figure: The PharmaVitae Explorer
* Figure: UCB's prescription pharmaceutical performance, sales ($m) and growth rate 2005-17
* Figure: UCB's financial performance ($m), 2005-17
* Figure: UCB's launch/core/expiry configuration ($m), 2011-17
* Figure: UCB epilepsy portfolio sales ($m), 2005-17
* Figure: UCB pharmaceutical sales, by geographic region ($m), 2005-17
* Figure: UCB's corporate structure
* Figure: UCB's operating revenue/cost analysis ($m), 2005-17

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.